NOA - Neuroonkologische Arbeitsgemeinschaft

Archive Studies

MecMeth/NOA-24
STUDY STATUS: active

Phase I/II study of combined therapy with meclofenamate and temozolozomide in the first recurrence of MGMT-methylated glioblastoma.

DIRECTOR
STUDY STATUS: completed

Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma

EORTC 26053 / CATNON / NOA
STUDY STATUS: active

Phase III trial on radio-chemotherapy of anaplastic gliomas without combined loss of 1p and 19q

NOA-10 / GLIAA-Studie
STUDY STATUS: active

Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma – a randomised phase II trial

NOA-11 / PDT
STUDY STATUS: active

Controlled clinical trial to evaluate the safety and efficacy of stereotactic photodynamic therapy with 5-aminolevulinic acid (Gliolan) in recurrent glioblastoma

NOA-13 / Registry Study
STUDY STATUS: active

Prospective observational study on chemotherapy in non-pre-treated patients with primary CNS lymphoma (PCNSL)

NOA-14 / HIPPORAD study
STUDY STATUS: active

Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging. Prospective, randomized, multicenter phase II study (Funding: German Cancer Aid)

NOA-16
STUDY STATUS: active

Targeting IDH1R132H in WHO grade III-IV IDH1R132H-mutated gliomas by a peptide vaccine – a phase I safety, tolerability and immunogenicity multicenter trial

NOA-17 / GlioCave
STUDY STATUS: active

A Phase II-Trial comparing adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma to observation

NOA-18 / Improve Codel
STUDY STATUS: Planned

Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q – Improve Codel: the NOA-20 trial

NOA-19 / ReCog-GBM-L
STUDY STATUS: active

Retest reliability and localization-dependent sensitivity of neurocognitive testing in first diagnosed glioblastoma patients (Re-Cog-GBM-L) – (Funding: University Hospital Cologne, Neurosurgery)

NOA-20 / N²M²
STUDY STATUS: active

Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match – N²M² (NOA-20)